

**CENTRAL NEW JERSEY MULTIPLE MYELOMA SUPPORT GROUP  
JANUARY 6, 2021**

**VIRTUAL MEETING RECAP**

This was an open meeting and there were 34 members in attendance virtually, of which two were new members.

We discussed...

- Speakers/topics for 2021. Below are some of the suggestions, and some speaker/topics that are already scheduled
  - Social Worker
  - Presentation on Lab Values
  - Kim Noonan RN, Managing Symptoms and Side Effects
  - Dr. Richter, MM Specialist
  - Dr. Biran, MM Specialist
  - Update on MMRF Genetics/Targeted Therapies
  - Dr. Strair, Cancer Institute of NJ

**Please continue to provide us with your speaker/topic suggestions!!**

Our speaker for February will be Kelly Sidorowicz, IMF who will give us an update on ASH 2020.

- COVID-19 Vaccine – This was a “round table” discussion regarding how our member’s physicians feel about them receiving the new vaccine

- At the request of a member a discussion was held on the topic of having a port installed...pros/cons
- We checked in with all of members in attendance and heard about any treatment updates, and/or concerns they had. We also met our new members and heard about their journeys

Below are informational Myeloma links, as well as informational Myeloma/COVID-19 links

**CENTRAL NEW JERSEY MULTIPLE MYELOMA SUPPORT GROUP  
MEETING RECAP FOR  
JANUARY 6, 2021 VIRTUAL MEETING  
MYELOMA/COVID-19 INFORMATIONAL LINKS**

**International Myeloma Foundation**

<https://www.myeloma.org/covid-19-vaccination-myeloma-patients>

- COVID-19 Vaccination and Myeloma Patients

<https://www.myeloma.org/covid19-myeloma-patients>

- COVID-19 FAQ #25: How can the “Swiss cheese” model help myeloma patients stay safe?
- <https://www.nytimes.com/2020/12/05/health/coronavirus-swiss-cheese-infection-mackay.html>

## **Myeloma Crowd**

<https://www.myelomacrowd.org/>

- Fast Development of COVID Vaccine: Not A Reason for Concern
- What Myeloma Patients Receiving COVID Vaccinations Need to Know
- ASH 2020: Dr. Fauci Opens with Reflections on COVID-19
- COVID-19 Isolation Precautions for Immunocompromised Patients
- Full Show: The IMPACT of COVID-19 on MGUS, Smoldering Myeloma, African Americans and Myeloma Patient Family Members
  - <https://www.myelomacrowd.org/full-show-the-impact-of-covid-19-on-mgus-smoldering-myeloma-african-americans-and-myeloma-patient-family-members/>

## **Cure**

<https://www.curetoday.com/search?searchTerm=covid>

- Sizing Up the COVID-19 Vaccines: What Patients with Cancer Should Know

## **Leukemia and Lymphoma Society**

<https://www.lls.org/covid-19-vaccines-faq>

- COVID-19 VACCINES FAQ FOR PATIENTS AND CAREGIVERS

## CENTRAL NEW JERSEY MULTIPLE MYELOMA SUPPORT GROUP

### JANUARY 6, 2021 VIRTUAL MEETING RECAP

#### MYELOMA INFORMATIONAL LINKS

#### International Myeloma Foundation

<https://www.myeloma.org/>

- Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
- NCCN Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma
- Submission of Biologics License Application to FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Myeloma Has Been Initiated
- #AskDrDurie
  - Are four-drug combinations more effective than three-drug combinations?
  - What should myeloma patients do when a low level of myeloma protein remains detectable?
- International Myeloma Working Group

- IMWG Conference Series: ASH 2020
- ASH
  - Short videos regarding MM treatments presented at ASH 2020
  - <https://www.myeloma.org/imf-videos>
- Diversity
  - <https://www.myeloma.org/diversity/diversity-inclusion>
- Veterans against Myeloma
  - <https://veterans.myeloma.org/about-us/>
- Financial Assistance
  - <https://www.myeloma.org/online-resources>
- IMF Infoline - 800-452-2873 or at [infoline@myeloma.org](mailto:infoline@myeloma.org)
  - “With a focus on the health and well-being of our staff given the growing concerns over the COVID-19 (coronavirus), the IMF’s physical offices will close...with a reopen date to be determined. During this time, we recommend if you have questions for the InfoLine, please leave a message at 1-800-452-2873 or at [infoline@myeloma.org](mailto:infoline@myeloma.org). We will not be able to respond in real-time, but we will get back to all inquiries in the order they have been received”

**Multiple Myeloma Research Foundation**

<https://themmrf.org/>

January 23, 2021 @ 1:00 pm - 4:45 ET pm

### MMRF Virtual Patient Summit

- <https://themmrf.org/event/mmrf-virtual-patient-summit-2/>

January 28, 2021 @ 1:00 pm - 2:00 ET pm

### MMRF Patient Webinar Series- Maintenance Therapy for Myeloma Patients

- <https://themmrf.org/event/mmrf-patient-webinar-series-maintenance-therapy-for-myeloma-patients/>

### News, Press Releases, Blogs

- <https://themmrf.org/about/news-press-and-blogs/>
- Financial Assistance
  - <https://themmrf.org/resources/financial-assistance/>
- Resources/Education Programs
  - High Impact Topics Videos
  - Expert Sessions
- Research
  - <https://themmrf.org/finding-a-cure/our-work/>
    - Immunotherapy
    - The MMRF CureCloud
    - The CoMMpass Study

- MMRC
- MyDRUG

## **Myeloma Crowd**

<https://www.myelomacrowd.org/>

- Treating High Risk Multiple Myeloma Patients With or Without Elotuzumab: Is There Benefit for Everyone with Quad Therapies?
- An On/Off Switch for CAR T Therapy in Multiple Myeloma
- ASH 2020: New Off-the-Shelf CAR T Early Results for Multiple Myeloma
- ASH 2020: Pathways Targeting Genetics of Myeloma Reconsidered
- ASH 2020: Five Myeloma Experts Discuss Treatment Preferences
- ASH 2020: Is More Better? Triplet vs. Quadruplet Drug Combinations in Newly Diagnosed Myeloma
- ASH 2020: The State of Myeloma Drug Development Remains Strong as CAR T Races On
- ASH 2020: High Risk Smoldering Myeloma-Is It Time To Treat?
- Blood Type and Multiple Myeloma Outcomes
- Pesticide Use Linked to Myeloma Precursor Condition
- Underweight or Overweight: Myeloma Patients Have the Best Outcomes with Stable, Healthy Weight

- Janssen Starts Rolling Submission of FDA Biologics License Application for cilta-cel Myeloma CAR-T Treatment

### HealthTree University

- HealthTree University: Know Your Therapy (BETA) (Part 1 of 3)
- HealthTree University: Relapsed and Refractory MM Treatment (Part 2 of 2)
- HealthTree University: Relapsed and Refractory MM Treatment (Part 1 of 2)
- HealthTree University: Precursor Conditions (Part 3 of 3)

### Financial Resources

- <https://www.myelomacrowd.org/financial-helpful-resources/>

### Myeloma Crowd Roundtables

- <https://www.myelomacrowd.org/myeloma-crowd-round-tables/>

### Myeloma Crowd Radio

<https://www.myelomacrowd.org/myeloma-crowd-radio-episodes/>

### Myeloma Beacon

<https://myelomabeacon.org/>

### Cure

<https://www.curetoday.com/tumor/myeloma>



- Novel Drug with Dexamethasone Safe in Heavily Pretreated Multiple Myeloma
- FDA Lifts Hold on Trial Assessing CAR T-Cell Product for Relapsed or Refractory Multiple Myeloma
- Clinical Trials on Smoldering Myeloma May Open Doors to More Precision Medicine
- Triple Therapy with Xpovio, Velcade and Dexamethasone Improved Progression-Free Survival in Multiple Myeloma
- FDA Approves Xpovio for Use with Velcade and Dexamethasone in Multiple Myeloma
- Understanding New Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

### **Onclive/Onclive Videos**

<https://www.onclive.com/clinical/multiple-myeloma>

### **Myeloma Research News**

<https://myelomaresearchnews.com/>

- PT-112 Shows Promise for Heavily Treated Myeloma Patients
- MMRF Invests in Indapta's Natural Killer Cell Therapy to Advance Clinical Trials
- FDA Approval Sought for Cilta-cel CAR T-cell Therapy
- FDA Approves Xpovio Triple Combo for Previously Treated Myeloma

- Bispecific Antibody Shows Early, Promising Responses in Trial
- CAR T-cell Therapy Cilta-cel Continues to Show Benefits in Heavily Treated Myeloma Patients
- Roche's Cevostamab Leads to Durable, Deep Responses in Heavily Pre-Treated Patients
- MMRF Joins Dana-Farber to Advance Research in Smoldering Myeloma

### **Patient Power**

<https://patientpower.info/multiple-myeloma/>

- Latest News on CAR T-Cell Therapy for Multiple Myeloma
- New Combination Therapy for Relapsed Multiple Myeloma
- Will Blenrep Improve Myeloma Treatment Options in 2021?
- Blenrep and New Clinical Trials for Multiple Myeloma
- What If I Become Resistant to Lenalidomide (Revlimid)?
- Multiple Myeloma Roundtable: Immunotherapies & MRD Debate
- Multiple Myeloma Answers Now: Is a Myeloma Cure on the Horizon?

### **HealthTree University**

<https://www.youtube.com/channel/UC27i8v856WBGy-4ONPJS0MQ>

- Lots of great, short, informative myeloma videos

## **Myeloma Hub**

<https://multiplemyelomahub.com/>

- Racial differences in clinical trial enrollment, treatment, and survival outcomes in MM
- Thrombosis and multiple myeloma
- CARTITUDE-1 results indicate deep and durable responses with cilta-cel for RRMM
- Prognostic biomarkers and staging in AL amyloidosis
- Can circulating tumor cell assessment by flow replace bone marrow aspirates to monitor SMM?
- Can single cell sequencing help to better define and monitor MM?

## **SparkCures**

<https://sparkcures.com/>

## **Myeloma Central**

<https://www.myelomacentral.com/>

## **Standing in the Gaap**

<https://www.myelomacentral.com/multiple-myeloma-african-americans/what-is-standing-in-the-gaap/>

## **Cancer.com**

<https://www.cancer.com/>

**American Society of Hematology (ASH)**

<https://www.hematology.org/>

**ASH Clinical News**

<https://www.ashclinicalnews.org/>

**Leukemia/Lymphoma Society**

<https://www.lls.org/>

